As a thrombolytic agent, application of recombinant tissue plasminogen activator (tPA) to ischemic stroke is limited by the narrow time window and side effects on brain edema and hemorrhage. This study examined whether tPA, administered by intranasal delivery directly targeting the brain and spinal cord, provides therapeutic benefit during the subacute phase after stroke. Adult male Wistar rats were subjected to permanent right middle cerebral artery occlusion (MCAo). Animals were treated intranasally with saline, 60 μg or 600 μg recombinant human tPA at 7 and 14 days after MCAo (n = 8/group), respectively. An adhesive-removal test and a foot-fault test were used to monitor functional recovery. Biotinylated dextran amine (BDA) was injected into the left motor cortex to anterogradely label the corticorubral tract (CRT) and the corticospinal tract (CST). Naive rats (n = 6) were employed as normal control. Animals were euthanized 8 weeks after stroke. Compared with saline treated animals, significant functional improvements were evident in rats treated with 600 μg tPA (p b 0.05), but not in 60 μg tPA treated rats. Furthermore, 600 μg tPA treatment significantly enhanced both CRT and CST sprouting originating from the contralesional cortex into the denervated side of the red nucleus and cervical gray matter compared with control group (p b 0.01), respectively. The behavioral outcomes were highly correlated with CRT and CST axonal remodeling. Our data suggest that delayed tPA intranasal treatment provides therapeutic benefits for neurological recovery after stroke by, at least in part, promoting neuronal remodeling in the brain and spinal cord.
Introduction
Recombinant tissue plasminogen activator (tPA) is the only FDA approved thrombolytic agent for acute treatment of ischemic stroke; however, the efficacy and safety of its therapeutic application are limited by the narrow 4.5-h treatment time window and adverse side effects on brain edema and hemorrhagic transformation (Cronin, 2010) . Presently, fewer than 5% of stroke patients in the United States receive tPA. For decades, the primary stratagem for stroke treatment has been focused on neuroprotection to reduce the cerebral infarction. Unfortunately, all neuroprotective agents developed in the laboratory have failed in clinical trials (Rother, 2008) . There is therefore a compelling need to develop neurorestorative therapies to enhance neurological recovery, by primarily treating the intact cerebral hemisphere and the compromised cerebral tissue to promote neuronal plasticity to compensate for the damaged tissue during the subacute and chronic phases after stroke.
tPA has pleiotropic actions in the brain besides its well established fibrinolytic action. It induces neural injury in the setting of acute stroke (Benchenane et al., 2004) . However, it is also involved in synaptic plasticity (Samson and Medcalf, 2006) , dendritic remodeling (Mataga et al., 2004) and axonal outgrowth (Minor et al., 2009 ). We have demonstrated that endogenous tPA mediates bone marrow stromal cell-induced neurite outgrowth and functional recovery after stroke (Shen et al., 2011) . Thus, we hypothesized that exogenous administration of tPA during the subacute phase may also provide beneficial effects on stroke recovery by promoting axonal remodeling.
The catalytic activity of tPA is rapidly inactivated through binding of protein inhibitors, primarily plasminogen activator inhibitor-I (PAI-1). The tPA/PAI-1 complex is cleared from the circulation by the liver. Therefore, tPA has a short half-life of 5 to 10 min in the bloodstream (Gravanis and Tsirka, 2008) . Intranasal delivery method has been demonstrated to directly target the brain and spinal cord along olfactory and trigeminal nerves innervating the nasal passages 
